SR-BI基因多态性对瑞舒伐他汀调脂疗效的影响

发布时间：2018-06-12 22:52

本文选题：清道夫受体BI + SR-BI　；参考：《西部医学》2016年11期

【摘要】：目的探讨SR-BI基因的多态性是否影响瑞舒伐他汀降脂的疗效。方法本研究检测了147例高脂血症患者和185例正常血脂患者,c.4GA,c.726+54CT和c.1050CT的单核苷酸多态性,血清脂质和载脂蛋白浓度。高脂血症患者瑞舒伐他汀治疗剂量为10mg/d。于治疗前及开始后第4、8、12周抽血进行血脂指标检查,分析血脂水平的变化情况。结果 SR-BI多态性频率在高脂血症患者组和正常血脂组之间相似(P0.05)。c.726+54CT的T等位基因与正常血脂组人群LDL-c浓度升高相关,与高脂血症组患者apoB和apoB/apoA1升高相关(P0.05)。携带c.1050C等位基因的高脂血症患者(CC和CT基因型)与TT基因型携带者比较,瑞舒伐他汀调脂治疗治疗后,前者总胆固醇、低密度脂蛋白、apoB、apoB/apoA1比率的变化较小(P0.05)。结论 SR-BI基因多态性和患者血清脂质浓度相关,c.1050CT单核苷酸多态性和瑞舒伐他汀调脂治疗反应性相关。
[Abstract]:Objective to investigate whether SR-BI gene polymorphism affects the effect of rosuvastatin on lipid reduction. Methods the single nucleotide polymorphisms, serum lipid and apolipoprotein concentrations in 147 patients with hyperlipidemia and 185 patients with normal blood lipid were detected by single nucleotide polymorphism (SNP), serum lipid and apolipoprotein (apolipoprotein) concentrations. Patients with hyperlipidemia were treated at a dose of 10 mg / d. Blood lipids were measured at 812 weeks before and after treatment, and the changes of blood lipid levels were analyzed. Results the frequency of SR-BI polymorphism in hyperlipidemia group and normal blood lipid group was similar to that in hyperlipidemia patients. The T allele of c. 726 54 CT was correlated with the increase of LDL-c concentration in normal blood lipid group, and the increase of apoB and apoA1 level in hyperlipidemia group was associated with the increase of apoB and apoA1 in hyperlipidemia group. CC and CT genotypes of hyperlipidemia patients with c 1050C allele) compared with TT genotype carriers, the changes of total cholesterol and low density lipoprotein apoB / apoA1 ratio in patients with hyperlipidemia were smaller than those in patients with TT genotype. Conclusion SR-BI gene polymorphism is associated with serum lipid concentration and serum lipid concentration.
【作者单位】：浦东新区人民医院心血管内科;
【分类号】：R589.2

【相似文献】